Cdymax (India) Pharma Private Limited

FDA inspection history across 2 sites, 2019 to 2025

1
Warning letter
1
Form 483

Every document, by year

  • Warning letter
  • Form 483

2019: one Form 483; 2025: one warning letter.

The story so far

Built from the dates and citations on the documents themselves.

  1. 2019One Form 483, at Bengaluru, India.
  2. 2025One warning letter, at Bangalore, India.

Cited most

Across all Cdymax (India) Pharma Private Limited observations on file

The complete Cdymax (India) Pharma Private Limited file.

All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.

$198

The price of the documents, added to your cart together

Sites

Documents

2 on file, newest first
DateDocumentPrice
2025-11-13Warning letter Warning letter$99
2019-05-17483 Form 483$99

Investigators on these documents

Gam S. Zamil (1)

FEI number 3009882550 · most recent document Nov 13, 2025

About Cdymax (India) Pharma Private Limited

How many FDA Form 483s has Cdymax (India) Pharma Private Limited received?

FDA Intel has 1 Form 483 on file for Cdymax (India) Pharma Private Limited; the most recent is dated May 17, 2019.

When was Cdymax (India) Pharma Private Limited last inspected by FDA?

The most recent FDA inspection document on file for Cdymax (India) Pharma Private Limited is a Form 483 dated May 17, 2019, for the site in Bengaluru, India.

What did FDA cite at Cdymax (India) Pharma Private Limited?

The regulations cited most in the observations on file for Cdymax (India) Pharma Private Limited are 21 CFR 211.160 (General requirements), 1 time.

Has Cdymax (India) Pharma Private Limited received an FDA warning letter?

Yes. FDA Intel has 1 FDA warning letter on file for Cdymax (India) Pharma Private Limited; the most recent is dated Nov 13, 2025.